Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement

BMJ. 2000 Feb 19;320(7233):511-2.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Carbamates / therapeutic use*
  • Clinical Trials as Topic*
  • Humans
  • Neuroprotective Agents / therapeutic use*
  • Patient Selection
  • Phenylcarbamates*
  • Rivastigmine

Substances

  • Carbamates
  • Neuroprotective Agents
  • Phenylcarbamates
  • Rivastigmine